Q BioMed, Inc. operates as a biomedical acceleration and development company. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2014-11-17. The firm is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Company’s pipeline products include Strontium89, QBM-001, UTTROSIDE-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. QBM-001 is designed to alleviate the condition and allow toddlers to actively develop language and speech and avoid life-long speech and intellectual disabilities caused from being non-verbal. UTTROSIDE-B is a potential chemotherapeutic for liver cancer. MAN-01 is for the treatment of primary open-angle glaucoma, wherein it is developing a small molecule in the form of an easy to administer eye drop to reduce intra-ocular eye pressure (IOP), a key risk factor in the progression of glaucoma.
Follow-Up Questions
Qui est le CEO de Q BioMed Inc ?
Mr. Denis Corin est le Chairman of the Board de Q BioMed Inc, il a rejoint l'entreprise depuis 2015.
Quelle est la performance du prix de l'action QBIO ?
Le prix actuel de QBIO est de $0.0001, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Q BioMed Inc ?
Q BioMed Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Q BioMed Inc ?
La capitalisation boursière actuelle de Q BioMed Inc est de $14509
Est-ce que Q BioMed Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Q BioMed Inc, y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte
